Mark Kotter is a neurosurgeon, stem cell biologist, and CEO and founder of bit.bio. Bit.bio is an award-winning human synthetic biology company providing human cells for research, drug discovery, and cell therapy. Bit.bio applies a patented safe harbor gene targeting approach to inducibly express transcription factor combinations that reprogram human-induced pluripotent stem cells into highly defined and mature human cell types. Bit.bio spun out of the University of Cambridge in 2016 and has since raised approximately $200 million from Arch Ventures, Foresight Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, and Pulau Capital, among others.
In addition to bit.bio, Mark is also the co-founder of Meatable, scientific founder and chairman of rejuvenation startup clock.bio, and co-founder and trustee of Myelopathy.org, the first charity dedicated to a common yet often overseen condition causing a slow-motion spinal cord injury. Mark has also been a professor and researcher at Cambridge for more than 15 years. His diverse experience as an academic and serial entrepreneur offers a wealth of insights aspiring scientist founders can draw from.
Democratizing Access to Cells & the Evolution of bit.bio | A Financial Journey from Angel Investment to IPO | Building a Tech Bio Platform & Mark’s 10-Year Vision
Success in Academia vs. Industry | Vital Things All Founders Should Know | The Importance of Company Culture | bit.bio & the Operating System of Life
Navigating Between the Clinical & Research Worlds | Lessons in Combining Different Fields | The Evolution of Cell Therapies | Transitioning from Academia to Entrepreneurship
Childhood Experiences in Different Countries | Overcoming Dyslexia & Developing Math Skills | Pivoting His Career to Science and Medicine | Facilitating Curiosity Via Research & Lab Experiences
Start listening to TBSP episodes on your favorite platform. Subscribe to stay up to date on new episodes.